AMGEN PRESENTS NEW DATA FROM PHASE 2 TRIAL OF DAZODALIBEP IN SJÖGREN'S SYNDROME AT ACR 2023
First Phase 2 Trial in Sjögren's to Achieve the Primary Endpoint Both in Patients With Severe Symptomatology and Those With Systemic Disease
Results From Crossover Period Provide Further Evidence of the Clinical Efficacy and Safety of Dazodalibep in Sjögren's
The Phase 2 study of dazodalibep, a CD40 ligand antagonist in clinical development, was a randomized, double-blind, placebo-controlled crossover study evaluating two Sjögren's populations: patients with moderate to severe systemic disease activity and those with moderate to severe symptomatology despite lacking additional organ involvement. In
"To date, there are no FDA-approved disease-modifying treatments for Sjögren's and the positive results from the Phase 2 trial provide evidence that dazodalibep may address the underlying causes of the disease by reducing systemic disease activity and improving the debilitating symptoms such as dryness and fatigue," said
The company is advancing a Phase 3 trial evaluating the benefit of dazodalibep in Sjögren's.
Patients with Moderate to Severe Systemic Disease Activity
The first patient population included patients with moderate to severe systemic disease activity as defined by a EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI) score ≥5.
Key findings include:
- Patients who transitioned from placebo to dazodalibep experienced an improvement in their disease activity from Day 169 (4.1-point reduction in total ESSDAI score) to Day 365 (6.3-point reduction).
- At Day 365, patients who transitioned to dazodalibep also showed greater improvements in ESSDAI response rate (3- to 4-point reduction), EULAR Sjögren's Syndrome Patient Reported Index (ESSPRI) score and fatigue compared to those who transitioned to placebo.
- Dazodalibep was generally safe and well tolerated.
Patients with Moderate to Severe Symptomatology
The second patient population studied included those with moderate to severe symptomatology including dryness, fatigue and pain despite lacking additional organ involvement as defined by an ESSPRI score ≥5 and an ESSDAI score of <5.
Key findings include:
- Patients who transitioned from placebo to dazodalibep experienced further improvement in total ESSPRI score from Day 169 (0.5-point reduction) to Day 365 (1.3-point reduction).
- For patients who transitioned from dazodalibep to placebo, the improvements in total ESSPRI score achieved at Day 169 (1.8-point reduction) were largely sustained through Day 365 (1.9-point reduction).
- Patients who transitioned to dazodalibep also showed improvements in measurements of fatigue and the Patient Global Impression of Severity (PGI-S) from Day 169 to Day 365.
- Dazodalibep was generally safe and well tolerated.
"Sjögren's can be a devastating disease that significantly impacts a person's quality of life and can lead to serious medical outcomes," said
Dazodalibep is a CD40 ligand antagonist that blocks T cell interaction with CD40-expressing B cells, disrupting the overactivation of the CD40 ligand co-stimulatory pathway. Several autoimmune diseases are associated with the overactivation of this pathway.
About Sjögren's Syndrome
Sjögren's syndrome is a chronic, systemic autoimmune disease affecting exocrine glands, primarily the salivary and tear glands, with severe cases affecting multiple organs. Like other autoimmune diseases, Sjögren's syndrome primarily affects women. The disease also has an increased risk of non-Hodgkin's B-cell lymphoma and there is an unmet medical need for patients with extraglandular disease manifestations, as currently there is no therapy that can improve or slow the course of the disease. Disease manifestations include dry mouth, dry eyes, arthritis and kidney or lung dysfunction.
Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.
Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world's leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.
Amgen is one of the 30 companies that comprise the Dow Jones Industrial Average and is also part of the Nasdaq-100 index. In 2023,
This news release contains forward-looking statements that are based on the current expectations and beliefs of
No forward-looking statement can be guaranteed and actual results may differ materially from those we project. Discovery or identification of new product candidates or development of new indications for existing products cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate or development of a new indication for an existing product will be successful and become a commercial product. Further, preclinical results do not guarantee safe and effective performance of product candidates in humans. The complexity of the human body cannot be perfectly, or sometimes, even adequately modeled by computer or cell culture systems or animal models. The length of time that it takes for us to complete clinical trials and obtain regulatory approval for product marketing has in the past varied and we expect similar variability in the future. Even when clinical trials are successful, regulatory authorities may question the sufficiency for approval of the trial endpoints we have selected. We develop product candidates internally and through licensing collaborations, partnerships and joint ventures. Product candidates that are derived from relationships may be subject to disputes between the parties or may prove to be not as effective or as safe as we may have believed at the time of entering into such relationship. Also, we or others could identify safety, side effects or manufacturing problems with our products, including our devices, after they are on the market.
Our results may be affected by our ability to successfully market both new and existing products domestically and internationally, clinical and regulatory developments involving current and future products, sales growth of recently launched products, competition from other products including biosimilars, difficulties or delays in manufacturing our products and global economic conditions. In addition, sales of our products are affected by pricing pressure, political and public scrutiny and reimbursement policies imposed by third-party payers, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment. Furthermore, our research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. Our business may be impacted by government investigations, litigation and product liability claims. In addition, our business may be impacted by the adoption of new tax legislation or exposure to additional tax liabilities. If we fail to meet the compliance obligations in the corporate integrity agreement between us and the
The scientific information discussed in this news release related to our product candidates is preliminary and investigative. Such product candidates are not approved by the
View original content to download multimedia:https://www.prnewswire.com/news-releases/amgen-presents-new-data-from-phase-2-trial-of-dazodalibep-in-sjogrens-syndrome-at-acr-2023-301979208.html